<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22218">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817594</url>
  </required_header>
  <id_info>
    <org_study_id>P15-788</org_study_id>
    <nct_id>NCT02817594</nct_id>
  </id_info>
  <brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (3DUTCH)</brief_title>
  <acronym>3DUTCH</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in The Netherlands (3DUTCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The interferon-free combination regimen of Paritaprevir/r - Ombitasvir with or without
      Dasabuvir (ABBVIE REGIMEN) ± Ribavirin (RBV) for the treatment of chronic hepatitis C (CHC)
      has been shown to be safe and effective in randomized controlled clinical trials with strict
      inclusion and exclusion criteria under well controlled conditions.

      This observational study is the first effectiveness research examining the ABBVIE REGIMEN ±
      RBV, used according to local label, under real world conditions in the Netherlands in a
      clinical practice patient population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
    <description>SVR12 defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level less than 50 IU/mL 12 weeks after the last dose of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with virological response at end of treatment (EoT).</measure>
    <time_frame>Up to EoT, maximum of 24 weeks</time_frame>
    <description>Virological response defined as HCV RNA level less than 50 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with relapse at EoT.</measure>
    <time_frame>Up to EoT, maximum of 24 weeks</time_frame>
    <description>Relapse defined as HCV RNA less than 50 IU/mL at EoT followed by HCV RNA greater than or equal to 50 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with breakthrough.</measure>
    <time_frame>Up to EoT, maximum of 24 weeks</time_frame>
    <description>Breakthrough defined as at least 1 documented HCV RNA less than 50 IU/mL followed by HCV RNA greater than or equal to 50 IU/mL during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants meeting on-treatment virologic failure.</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
    <description>On-treatment virologic failure defined as breakthrough (at least 1 documented HCV RNA less than 50 IU/mL followed by HCV RNA greater than or equal to 50 IU/mL during treatment) or failure to suppress (each measured on-treatment HCV RNA value greater than or equal to 50 IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants meeting premature study drug discontinuation</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
    <description>Defined as participants who prematurely discontinued treatment and who experienced no on-treatment virologic failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants meeting missing SVR12 data and/or none of the above criteria</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA (cumulative dose taken divided by target dose in percent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV (cumulative dose taken divided by target dose in percent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of missed Ribavirin (RBV) treatment days</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The percentage of missed Ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>HCV Genotype 1 or 4 participants</arm_group_label>
    <description>Participants receiving Paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with CHC, genotype 1 or , receiving combination therapy with the
        interferon-free ABBVIE REGIMEN ± RBV.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced adult male or female participants with confirmed CHC,
             genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE
             REGIMEN ± RBV according to standard of care and in line with the current local label.

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line
             with the current local label (with special attention to contraception requirements
             and contraindication during pregnancy).

          -  Participants must voluntarily sign and date informed consent prior to inclusion into
             the study

        Exclusion Criteria:

          -  Patients participating or intending to participate in a concurrent interventional
             therapeutic trial.

          -  Unable to complete the questionnaires due to cognitive impairment or lack of any kind
             of cognitive competence, as to be judged by the healthcare professional who is
             treating the patient.

          -  Unable to complete the questionnaires due to language incompetence.

          -  Unable to voluntarily sign and date the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Florentinus, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rien Dorland, PhD</last_name>
    <phone>(31)611392227</phone>
    <email>Rien.Dorland@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baukje Schotanus, PhD</last_name>
    <email>Baukje.Schotanus@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152604</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152604, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152600</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152600, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157896</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157896, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152597</name>
      <address>
        <city>Dordrecht</city>
        <zip>3317 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152597, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154636</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154636, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152596</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152596, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154637</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154637, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152605</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152605, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152598</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152598, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154635</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154635, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152592</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152592, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152595</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152595, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>June 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sustained Virological Response</keyword>
  <keyword>Chronic Hepatitis C genotype 4</keyword>
  <keyword>Chronic Hepatitis C genotype 1</keyword>
  <keyword>Observational Study</keyword>
  <keyword>Paritaprevir/r - Ombitasvir, ± Dasabuvir</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
